300434 Sichuan Goldstone
- 9.22
- -0.55-5.63%
Sichuan Goldstone News
Jinshi Ya Pharmaceutical: Announcement on the wholly owned Sun Company passing the GMP compliance inspection of the drug
Jinshi Asia Pharmaceutical: Announcement on the Wholly-owned Sun Company Obtaining a High-tech Enterprise Certificate
Jinshi Asia Pharmaceutical: Announcement of Resolutions of the 6th Meeting of the Fifth Board of Directors
Jinshi Asia Pharmaceutical: Announcement of Resolutions of the Fifth Meeting of the Fifth Board of Supervisors
Jinshi Asia Pharmaceutical: Announcement of Resolutions of the Fifth Meeting of the Fifth Board of Directors
Jinshi Asia Pharmaceutical: Announcement on attending the 2024 Online Investor Group Reception Day and Semi-Annual Results Briefing in the Sichuan Region
Jinshi Asia Pharmaceutical: Announcement of Board Resolutions
Jinshi Asia Pharmaceutical: Announcement of Supervisory Committee Resolutions
Sichuan Goldstone: 300434 Jinshi Asia Pharmaceutical Investor Relations Management Information 20240517
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Liu Chuwang)
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Zhu Jianwei)
Sichuan Goldstone: Announcement on the proposed renewal of financial auditors and internal control auditors in 2024
Sichuan Goldstone: Announcement on holding the 2023 online results briefing
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Miao Jianquan)
Sichuan Goldstone: Announcement of Board Resolutions
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Zhao Xiaowei)
Sichuan Goldstone: Assessment report on the recoverable value assets of the asset group portfolio involved in the proposed impairment test of goodwill formed by merging Hainan Asia Pharmaceutical Co., Ltd.
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Zhong Peng)
Sichuan Goldstone: The Board's special opinion on the sole director's independence assessment
Sichuan Goldstone: Asset group recyclable value asset assessment report involved in the proposed impairment test of goodwill formed by merging Zhejiang Jiande Zhengfa Pharmaceutical Co., Ltd.
No Data